Effects of a Collagen Supplement on Quality of Life, Appetite and Glycaemic Control

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a clinical trial aimed to investigate if a collagen supplement can improve quality of life, appetite and blood sugar in overweight and obese adults aged 18-65.

Hypothesis: Consumption of a collagen supplement for 8 days will improve quality of life and improve glycaemic control in comparison with a placebo in individuals overweight or with obesity with a perceived low quality of life.

Participants will be asked to:

1. Consume a collagen peptide supplement for a total of 8 days at a time
2. Fill in questionnaires about quality of life, appetite, mood and energy
3. Wear continuous glucose monitors

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Nextida-GC and Whey Protein on Postprandial Glycemic and Insulinemic Responses When Given 30min Before, 10min Before or With a Standardized Breakfast Test-meal in Healthy Adults With and Without Prediabetes

NCT07174323

Prediabetes Normal Plasma Glucose Normoglycemia

RECRUITING NA

To Collect Enriched Human Serum Following Hydrolyzed Collagen Intake

NCT07195396

Healthy Women

COMPLETED NA

Investigating the Effects of Glucodia™ on Glucose Parameters, Triglycerides and Body Weight

NCT02322294

Glucose Parameters Triglycerides Body Weight

COMPLETED PHASE2

Colonic Propionate, Appetite, and Weight Loss

NCT03322514

Healthy Obesity, Metabolically Appetite Regulation

COMPLETED NA

Investigating the Glycaemic and Satiating Capacity of PulseOn® Enriched Foods

NCT06508424

Glycaemic Response Appetitive Behavior Energy Intake

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Quality of Life Appetite Sleep Mood Energy Blood Glucose Profile

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Collagen peptide then placebo

2 x 5g of hydrolysed collagen peptide daily for 8 days then crossing over to the placebo

Group Type EXPERIMENTAL

Collagen peptide supplement

Intervention Type DIETARY_SUPPLEMENT

5 g of hydrolysed collagen peptide of bovine origin in powdered form. Taken twice daily for 8 days total.

Placebo

Intervention Type OTHER

5 g of maltodextrin in powdered form. Taken twice daily for 8 days total.

Placebo then collagen peptide

2 x 5g of maltodextrin daily for 8 days then crossing over to the collagen peptide

Group Type EXPERIMENTAL

Collagen peptide supplement

Intervention Type DIETARY_SUPPLEMENT

5 g of hydrolysed collagen peptide of bovine origin in powdered form. Taken twice daily for 8 days total.

Placebo

Intervention Type OTHER

5 g of maltodextrin in powdered form. Taken twice daily for 8 days total.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collagen peptide supplement

5 g of hydrolysed collagen peptide of bovine origin in powdered form. Taken twice daily for 8 days total.

Intervention Type DIETARY_SUPPLEMENT

Placebo

5 g of maltodextrin in powdered form. Taken twice daily for 8 days total.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is a healthy (as assessed by medical history) male or female adult, aged 18-65 years and overweight or obese (BMI 25 - 40 kg/m2).
2. Subject has an impaired quality of life, as determined by scoring at least a total of 9 on the following questions:

1. In the past 4 weeks, did you feel you had a lot of energy? All of the time (1), most of the time (2), a good bit of the time (3), some of the time (4), a little of the time (5), and none of the time (6) (number 27 from SF-36 questionnaire) Version 3.0 \[01/10/2025\] Page 11 of 20
2. In the past 4 weeks, have you felt calm and peaceful? All of the time (1), most of the time (2), a good bit of the time (3), some of the time (4), a little of the time (5), and none of the time (6) (number 26 from SF-36 questionnaire)
3. In the past 2 weeks, did you have any difficulties with sleeping? Not at all (1), small amounts (2), moderate amounts (3), a great deal (4), an extreme amount (5), all the time (6) (number 3 from WHOQoL-100)
3. Participant has an email address, internet access, a compatible smartphone and is willing and able to maintain internet access throughout the trial to complete virtual visits via video conference and to engage with mobile apps to answer electronic questionnaires.
4. Subject is willing and able to comply with all study procedures, including consumption of the supplement daily, CGM use for 22 days total (2 x 11 days), complete standardised meal tests, and fill out health questionnaires.
5. Subject is willing to take a supplement of bovine animal origin.
6. Openness to participate in an online interview at the end of the study.

Exclusion Criteria

1. Participant has a history or presence of uncontrolled and/or clinically important pulmonary, cardiac, hepatic, renal, endocrine (including type 1 and 2 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or Parkinson's diseases), psychiatric (including unstable depression and/or anxiety disorders) or biliary disorders.
2. Participant has a clinically important gastrointestinal (GI) condition that would potentially interfere with the evaluation of the study product \[e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation, severe constipation (in the opinion of the investigator), history of frequent diarrhoea, history of surgery for weight loss, gastroparesis, systemic disease that might affect gut motility according to the investigator, medication managed reflux and/or clinically important lactose intolerance.
3. Participant has a history of chronic insomnia (defined as insomnia at least 3 d/week over the past month), a diagnosed sleep disorder (e.g., OSA), or a chronic medical condition that may impact energy/fatigue levels, in the judgment of the investigator.
4. Participant is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded.
5. Participant has a known allergy, intolerance, or sensitivity to any of the ingredients in the study product, including bovine animal products.
6. Participant has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
7. Participant has experienced any major trauma or any other surgical event within three months of Virtual Visit 1.
8. Participant has unstable use of a medication or supplement that the investigator considers may affect the outcomes of the trial.
9. Participant is currently in another biomedical research study or has been in the 30 days before screening.
10. Participant is an employee of, or has a financial interest in Darling Ingredients Inc.
11. The individual has a condition the investigator believes would interfere with his ability to provide informed consent and to comply with the study protocol, which might confound the interpretation of the study results, or put the participant at undue risk.
12. Participant is a vegan or vegetarian or excludes bovine products for cultural or religious reasons.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes